Table 5. Engraftment of AML cells in... | American Society of Hematology

Table 5.

Engraftment of AML cells in different phases of the cell cycle in NOD/SCID mice

Unsorted		G₀		G₁		S/G₂ + M
Cell dose per mouse^5-150	% CD45⁺ cells^5-151	Cell dose per mouse^5-150	% CD45⁺ cells^5-151	Cell dose per mouse^5-150	%CD45⁺ cells^5-151	Cell dose per mouse^5-150	%CD45⁺ cells^5-151
Patient 1
100	0.58, 0.35, 0, 0.1, 2.8, 0.88	8	0.12, 0.18	8	0	1	0,0
		1	0.22, 0	4	0	0.1	0,0
		0.1	0, 0	1	0
Patient 2
10	99.4, 86.5, 76.7	1	90.6, 43.8, 74.0	4	2.3, 1.7	0.2	0,0
1	8.2, 19.3, 21.5	0.1	39.9, 39	1	0, 0.19	0.1	0,0
		0.01	0, 0.12	0.1	0, 0
Patient 4
10	0.4, 0.44	2	7.2, 0.44	10	0, 0.27	2	0,0
5	0.34, 0	0.2	0, 0, 0	1	0, 0	0.02	0
1	0, 0	0.02	0, 0, 0	0.1	0, 0
Patient 5
50	93.0, 82.9, 2.9	2	79.6, 81.1	10	0	2	0,0
5	14.2, 2.7, 0.15	0.1	1.7, 0.19, 0.29	1	0, 0	0.2	0,0
		0.01	0, 0, 0	0.1	0, 0	0.02	0,0

Unsorted		G₀		G₁		S/G₂ + M
Cell dose per mouse^5-150	% CD45⁺ cells^5-151	Cell dose per mouse^5-150	% CD45⁺ cells^5-151	Cell dose per mouse^5-150	%CD45⁺ cells^5-151	Cell dose per mouse^5-150	%CD45⁺ cells^5-151
Patient 1
100	0.58, 0.35, 0, 0.1, 2.8, 0.88	8	0.12, 0.18	8	0	1	0,0
		1	0.22, 0	4	0	0.1	0,0
		0.1	0, 0	1	0
Patient 2
10	99.4, 86.5, 76.7	1	90.6, 43.8, 74.0	4	2.3, 1.7	0.2	0,0
1	8.2, 19.3, 21.5	0.1	39.9, 39	1	0, 0.19	0.1	0,0
		0.01	0, 0.12	0.1	0, 0
Patient 4
10	0.4, 0.44	2	7.2, 0.44	10	0, 0.27	2	0,0
5	0.34, 0	0.2	0, 0, 0	1	0, 0	0.02	0
1	0, 0	0.02	0, 0, 0	0.1	0, 0
Patient 5
50	93.0, 82.9, 2.9	2	79.6, 81.1	10	0	2	0,0
5	14.2, 2.7, 0.15	0.1	1.7, 0.19, 0.29	1	0, 0	0.2	0,0
		0.01	0, 0, 0	0.1	0, 0	0.02	0,0

Number of AML cells injected per mouse on day 0 (× 10⁵).

Percentage of CD45⁺ cells detected at 8 to 12 weeks after injection in each mouse previously injected with the indicated dose of AML cells.